Celldex Therapeutics, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparative period is Q1 2022. Celldex is a clinical-stage biopharmaceutical company focused on antibody therapies. Its principal program is barzolvolimab (CDX-0159), with additional development of a bispecific antibody platform.
Financial results and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $1.0 million | $0.2 million; up $0.8 million |
| Research and development expense | $26.8 million | $17.1 million; up 57% |
| General and administrative expense | $6.6 million | $6.9 million; down 4% |
| Operating loss | $32.5 million | $23.3 million |
| Investment and other income | $3.1 million | $0.2 million |
| Net loss | $29.4 million | $23.1 million |
| Basic and diluted loss per share | $0.62 | $0.49 |
| Net cash used in operating activities | $28.6 million | $24.5 million |
Revenue was primarily contracts and grants, including work for Rockefeller University; there was no product revenue. Gross profit and operating margins are not meaningful indicators for this development-stage business, and the filing does not provide margin measures.
At March 31, cash and cash equivalents were $54.1 million and marketable securities were $224.3 million, totaling $278.4 million. Current assets were $289.6 million and current liabilities were $15.2 million. Total liabilities were $21.8 million, including lease liabilities; the filing does not report funded debt. Stockholders’ equity was $302.7 million.
Material changes and drivers
- R&D expense rose $9.7 million, chiefly from barzolvolimab clinical-trial and contract-manufacturing costs; barzolvolimab/anti-KIT program costs increased to $17.7 million from $9.7 million.
- Net loss increased $6.3 million year over year, primarily because of higher R&D spending, partly offset by higher investment and other income.
- Investment and other income increased $2.9 million, reflecting higher interest rates and income recognized from the sale of New Jersey tax benefits.
- Operating cash use increased $4.0 million year over year. Cash and cash equivalents rose during the quarter, aided by net maturities and sales of marketable securities; this investing cash flow reflects portfolio activity, not operating cash generation.
Outlook, programs and risks
- Management said liquidity at March 31 was expected to fund planned operations through 2025, including ongoing and planned barzolvolimab trials. The financial-statement note separately states resources are expected to cover at least the next 12 months from issuance. The longer runway could be affected by future settlement milestones paid in cash.
- Management expects revenue to remain relatively consistent over the next 12 months, with quarterly fluctuations. It expects personnel costs to increase as development expands; other expense outlooks are generally described as relatively consistent, subject to fluctuations.
- For barzolvolimab, management expected Phase 2 CSU enrollment to finish in Q3 2023 and topline results in late 2023 or Q1 2024; Phase 2 EoE initiation was planned for June 2023. PN Phase 1b data were planned for Q4 2023, with a Phase 2 subcutaneous study expected in late 2023 or early 2024. CDX-585 was expected to enter clinical testing in mid-2023. These are forward-looking plans, not guaranteed outcomes.
- Management reported positive interim Phase 1b CSU findings, including symptom improvement and a generally favorable safety profile. It also disclosed adverse events including hair-color changes and neutropenia; clinical findings remain preliminary and require confirmation in larger studies.
- Liquidity risks include recurring losses, continued high R&D spending, uncertain clinical and regulatory outcomes, and possible need for additional capital. Financing may be unavailable or dilutive, and inability to raise funds could force trial delays, program licensing or discontinuation.
- A settlement with the former Kolltan stockholders replaced prior contingent milestones. Celldex paid $15 million in 2022; further payments include $15 million upon successful completion of a specified CDX-0159 Phase 2 trial, subject to a $2.5 million contractual credit, and $52.5 million upon the first specified U.S. or European regulatory approval. Future payments may be made in cash, shares or both, at Celldex’s option.
- The company reported no material changes to previously disclosed risk factors, no material impact from adopting the expected-credit-loss accounting standard, and effective disclosure controls as of March 31, 2023.
Important facts for investors to verify
- Whether trial enrollment, data-readout and initiation timelines remain on schedule, and how larger studies validate the early barzolvolimab findings.
- Actual quarterly cash burn and the assumptions behind management’s runway estimate through 2025, including any settlement milestone payments.
- R&D cost trends, especially clinical and manufacturing spending, relative to available cash and securities.
- The availability, terms and potential dilution of future financing or collaboration arrangements.
- Future clinical safety results, regulatory progress and any changes in the development strategy for barzolvolimab and CDX-585.